'World-first' vaccine designed by AI tested on humans: Will it live up to the hype?
Researchers at the University of Cambridge successfully tested the world’s first AI-designed vaccine in humans, targeting sarbecoviruses including SARS-CoV-2, with modest immune responses in a small trial of 39 participants. The needle-free vaccine uses AI to predict and target conserved viral regions, but further testing is required to confirm safety and effectiveness before potential real-world use.
Scientists at the University of Cambridge have developed the first vaccine designed entirely by artificial intelligence and completed initial human trials. The vaccine targets sarbecoviruses, a family that includes SARS and SARS-CoV-2, the virus responsible for COVID-19. Unlike traditional vaccines, this one uses AI to analyze multiple coronavirus strains and create a 'super antigen' that attacks common viral features, potentially offering protection against future mutations. The vaccine was administered using a needle-free jet injector system, which delivers the formulation through fluid dynamics instead of a traditional syringe. Early trials involved 39 participants and focused on safety, with results published in the *Journal of Infection*. While the vaccine demonstrated modest immune responses, it fell short of the robust protection needed for universal coronavirus immunity. A second trial with 200 participants is underway to assess effectiveness. Experts, including infectious disease specialist Monica Gandhi from the University of California, San Francisco, noted that prior exposure to SARS-CoV-2 likely influenced the trial results, as most adults worldwide have already encountered the virus. AI scientist Marc Boubnovski from Novo Nordisk emphasized that larger trials are necessary before determining whether the vaccine can provide broad, lasting immunity. The technology remains experimental, and the small initial trial highlights the challenges of developing a universal vaccine. Researchers stress that further testing is critical to validate safety and efficacy before considering widespread use. If successful, this AI-driven approach could revolutionize vaccine development for future pandemics.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.